| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||||||||
Net loss | ||||||||||||||||
-69,731 | 30,542 | 138,423 | -53,699 | -48,408 | -47,590 | -50,711 | -38,380 | -28,300 | 141 | -24,708 | -22,315 | -21,475 | 17,098 | -14,694 | -17,164 | -8,442 |
Reconciliation of net loss to net cash used in operating activities: | ||||||||||||||||
Depreciation and amortization | ||||||||||||||||
2,091 | 1,432 | 1,283 | 1,198 | 812 | 945 | 883 | 865 | 826 | 806 | 792 | 706 | 720 | 412 | 236 | 171 | 106 |
Equity-based compensation | ||||||||||||||||
14,151 | 11,857 | 11,343 | 11,186 | 9,671 | 13,025 | 8,054 | 8,324 | 5,582 | 6,979 | 4,868 | 3,726 | 3,300 | 4,028 | 2,293 | 3,501 | 1,022 |
Loss from equity method investment | ||||||||||||||||
- | 0 | -3,430 | -1,012 | -1,025 | -1,019 | -1,012 | -1,153 | -1,091 | -453 | -359 | -505 | -446 | - | - | - | - |
Other expense, non-cash | ||||||||||||||||
890 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Non-cash interest | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 8,050 |
Loss from disposal of property and equipment | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -28 |
Unrealized foreign currency remeasurement (gain) loss | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 10 | -1 | -9 | 21 | -3 | -11 |
Gain on extinguishment of convertible loan | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 11,482 |
Changes in: | ||||||||||||||||
Restricted cash | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 2,451 | 2 |
Accounts receivable | ||||||||||||||||
25,018 | 60 | -282 | -10 | 243 | -464 | -392 | -316 | -1,366 | -585 | -3,603 | 1,142 | 2,515 | 1,065 | 738 | 389 | 626 |
Prepaid expenses and other assets | ||||||||||||||||
-29,659 | 7,276 | 23,943 | -1,652 | 3,051 | 840 | -1,302 | 1,378 | 2,426 | 3,813 | -432 | 342 | 394 | 377 | -1,879 | 1,580 | 993 |
Accounts payable and accrued expenses | ||||||||||||||||
-2,496 | 4,605 | 1,269 | 2,475 | -3,324 | 4,128 | 4,218 | 4,203 | -439 | 2,148 | -876 | 1,545 | -3,648 | 585 | -1,713 | 3,032 | 1,956 |
Deferred revenue | ||||||||||||||||
-157 | -46,860 | 1,764 | -25 | -25 | -26 | -26 | -26 | -218 | -22,761 | 457 | 921 | 665 | 697 | 510 | 559 | 151 |
Deferred rent | ||||||||||||||||
- | - | - | - | - | -181 | -147 | -186 | -195 | 381 | -548 | 160 | -515 | 2,164 | 12 | 12 | 172 |
Operating lease assets and liabilities | ||||||||||||||||
37 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other liabilities, net | ||||||||||||||||
-1,601 | 25,110 | -133 | 200 | -194 | 211 | -50 | 63 | 25 | 239 | -247 | 274 | 4 | -28 | -40 | 16 | 35 |
Net cash used in operating activities | ||||||||||||||||
-52,175 | 3,376 | 133,420 | -36,382 | -43,737 | -28,372 | -19,964 | -25,215 | -22,688 | -14,842 | -15,868 | -15,972 | -23,411 | -16,966 | -12,276 | -13,604 | -10,014 |
Purchase of property and equipment | ||||||||||||||||
2,991 | 952 | 2,461 | 2,174 | 1,097 | 1,000 | 695 | 523 | 555 | 205 | 2,994 | 1,330 | 3,285 | 228 | 1,509 | 1,047 | 232 |
Proceeds from contribution of intellectual property to equity method investee | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 15,000 | 0 | 0 | 20,000 |
Cash investment in equity method investee | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 100 |
Net cash used in investing activities | ||||||||||||||||
-2,991 | 7,057 | -2,461 | -2,174 | -1,097 | -1,000 | -695 | -523 | -555 | -205 | -3,494 | -1,330 | -3,285 | 14,772 | -1,509 | -1,047 | 19,668 |
Proceeds from issuance of common shares, net of issuance costs | ||||||||||||||||
- | 293,803 | 68,922 | 28,400 | 23,894 | -1,966 | 186,422 | 0 | 122,597 | - | - | - | - | - | - | - | - |
Proceeds from exercise of options, net of issuance costs | ||||||||||||||||
1,132 | 10,915 | 1,963 | 1,254 | 1,832 | 697 | 1,808 | 3,779 | 2,654 | 1,284 | 609 | 695 | 20 | - | - | - | - |
Proceeds from issuance of convertible loans | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 10 | 0 | 0 | 35,000 |
Net cash provided by financing activities | ||||||||||||||||
1,132 | 304,718 | 70,885 | 29,654 | 25,726 | -1,269 | 188,223 | 3,729 | 125,251 | 1,284 | 609 | 695 | 20 | 91,766 | -4,471 | 60,925 | 35,000 |
Effect of exchange rate changes on cash | ||||||||||||||||
-25 | 29 | -12 | -10 | 8 | -7 | -6 | -21 | 12 | 2 | 8 | 2 | 29 | -215 | 20 | -25 | -15 |
Decrease in cash | ||||||||||||||||
-54,059 | 315,180 | 201,832 | -8,912 | -19,100 | -30,648 | 167,558 | -22,030 | 102,020 | -13,761 | -18,745 | -16,605 | -26,647 | 89,357 | -18,236 | 46,249 | 44,639 |
Supplemental disclosure of non-cash investing and financing activities | ||||||||||||||||
Property and equipment purchases in accounts payable and accrued expenses | ||||||||||||||||
1,340 | 1,383 | -274 | 123 | 579 | - | - | -182 | 307 | - | -2,579 | 1,724 | 973 | 6,768 | 199 | -69 | 116 |
Equity issuance costs in accounts payable and accrued expenses | ||||||||||||||||
39 | - | 262 | 296 | 181 | - | - | - | - | - | - | - | - | - | - | - | - |
Conversion of Vertex and Bayer convertible loans and accrued interest | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 61,929 |
Contribution of intellectual property to Casebia | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 8 | 0 | 0 | 36,372 |